MNPR Overview

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Wall Street analysts forecast MNPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNPR is112.91 USD with a low forecast of 95.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Monopar Therapeutics Inc revenue for the last quarter amounts to -6.16M USD, decreased -44.42

Monopar Therapeutics Inc. EPS for the last quarter amounts to -3370070.00 USD, increased 68.64

Monopar Therapeutics Inc (MNPR) has 22 emplpoyees as of March 31 2026.

Today MNPR has the market capitalization of 361.53M USD.